Advertisement

Disturbance of the 5-hydroxytryptamine metabolism in brains from patients with Alzheimer’s dementia

  • C. G. Gottfries
Part of the Journal of Neural Transmission book series (NEURAL SUPPL, volume 30)

Summary

The 5-hydroxytryptamine (5-HT) system in the human brain is sensitive to aging. In dementia of the Alzheimer type (AD/SDAT), there are significantly reduced concentrations of 5-HT and 5-hydroxyindoleacetic acid (5-HIAA). 5-HT-sensitive imipramine binding is reduced by almost 50%, indicating a loss of presynaptic 5-HT terminals. There also seems to be reduced tryptophan hydroxylase activity in some brain areas. In cerebrospinal fluid (CSF) from AD/SDAT patients, the concentration of 5-HIAA is reduced, and the accumulation of 5-HIAA after probenecid loading is diminished. Biochemical findings together with structural findings in the raphe nuclei indicate that the disturbance of the 5-HT system is of the same magnitude as the disturbance of the cholinergic system.

Reduced activity in the 5-HT system may be of importance for activity in the hypothalamus. There is an increased concentration of arginine vasopressin, which may explain the increased activity in the hypothalamic-pituitary-adrenal axis seen in patients with AD/SDAT. This activity is reduced when a selective 5-HT reuptake blocker is given.

Pharmacological treatment with 5-HT reuptake blockers improves emotional disturbances, confusion, anxiety and depressed mood in patients with AD/SDAT.

Keywords

Raphe Nucleus Pernicious Anaemia Senile Dementia Presenile Dementia Dementia Disorder 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Adolfsson R, Gottfries CG, Roos BE, Winblad B (1981) Monoamines in the human brain in normal aging and in senile dementia. In: Marois M (ed) Aging — a challenge to science and social policy, vol 2. Oxford University Press, pp 238–247Google Scholar
  2. Arai H, Kosaka K, Iizuka R (1984) Changes of biogenic amines and their metabolites in postmortem brains from patients with Alzheimer-type dementia. J Neurochem 43:388–393PubMedCrossRefGoogle Scholar
  3. Balldin J, Gottfries CG, Karlsson I, Lindstedt G, Lângström G, Svennerholm L (1988) Relationship between DST and the serotonergic system. Results from treatments with two 5-HT reuptake blockers in dementia disorders. Int J Ger Psychiatry 3:17–26CrossRefGoogle Scholar
  4. Balldin J, Gottfries CG, Lindstedt G, Långström G, Svennerholm L (1988) The clonidine growth hormone test in patients with dementia disorders: relation to clinical status and cerebrospinal fluid metabolite levels. Int J Ger Psychiatry 3:115–123CrossRefGoogle Scholar
  5. Bucht G, Adolfsson R, Gottfries CG, Roos BE, Winblad B (1981) Distribution of 5-hydroxytryptamine and 5-hydroxyindoleacetic acid in human brain in relation to age, drug influence, agonal status, and circadian variations. J Neural Transm 51:185–203PubMedCrossRefGoogle Scholar
  6. Carlsson A, Adolfsson R, Aquilonius SM, Gottfries CG, Oreland L, Svennerholm L, Winblad B (1980) Biogenic amines in human brain in normal aging, senile dementia and chronic alcoholism. In: Goldstein M, et al (eds) Ergot compounds and brain function: neuroendocrine and neuropsychiatric aspects. Raven Press, New York, pp 295–304Google Scholar
  7. Carlsson A, Gottfries CG (1986) Neurotransmitter abnormalities in old age dementias. In: Leichner H, Paraschos A (eds) Proceedings of the 5th South-East European Neuropsychiatric Conference, Graz 1983. University Studio Press, Salonica, pp 634–645Google Scholar
  8. Carlsson A (1986) Neurotransmitters in old age and dementia. In: Hafner H, Moschel G, Sartorius N (eds) Mental health in the elderly: a review of the present state of research. Springer, Berlin Heidelberg New YorkGoogle Scholar
  9. Forssell LG, Eklöf R, Winblad B (1989) Early stages of late onset Alzheimer’s disease II. Derangements in protein metabolism with special reference to tryptophan, tyrosine and cystine. Acta Neurol Scand 79 [Suppl 121]: 27–42CrossRefGoogle Scholar
  10. Gottfries CG, Gottfries I, Roos BE (1969) Homovanillic acid and 5-hydroxyindoleacetic acid in the cerebrospinal fluid of patients with senile dementia, presenile dementia and Parkinsonism. J Neurochem 16:1341–1345PubMedCrossRefGoogle Scholar
  11. Gottfries CG, Gottfries I, Johansson B, Olsson R, Persson T, Roos BE, Sjöström R (1971) Acid monoamine metabolites in human cerebrospinal fluid and their relations to age and sex. Neuropharmacology 10:665–672PubMedCrossRefGoogle Scholar
  12. Gottfries CG, Roos BE (1973) Acid monoamine metabolites in cerebrospinal fluid from patients with presenile dementia (Alzheimer’s disease). Acta Psychiatr Scand 49:257–263CrossRefGoogle Scholar
  13. Gottfries CG, Roos BE, Winblad B (1976) Monoamine and monoamine metabolites in the human brain post mortem in senile dementia. Aktuelle Gerontologie 6:429–435Google Scholar
  14. Gottfries CG, Adolfsson R, Aquilonius SM, Carlsson A, Eckernäs SE, Nordberg A, Oreland L, Svennerholm L, Wiberg A, Winblad B (1983) Biochemical changes in dementia disorders of Alzheimer type (AD/SDAT). Neurobiol Aging 4:261–271PubMedCrossRefGoogle Scholar
  15. Gottfries CG, Bartfai T, Carlsson A, Eckernäs SA, Svennerholm L (1986) Multiple biochemical deficits in both gray and white matter of Alzheimer brains. Prog Neuropsychopharmacol Biol Psychiatry 10:405–413PubMedCrossRefGoogle Scholar
  16. Gottfries CG (1988) Alzheimer’s disease — a critical review. Compr Geronto 12:47–62Google Scholar
  17. Hardy J, Adolfsson R, Alafuzoff I, Bucht G, Marcusson J, Nyberg P, Perdahl E, Wester P, Winblad B (1985) Review. Transmitter deficits in Alzheimer’s disease. Critiques: Gottfries CG, Rossor MN, Yates CM. Neurochem Int 7:545–563Google Scholar
  18. Mann DMA, Yates PO (1983) Serotonin nerve cells in Alzheimer’s disease. J Neurol Neurosurg Psychiatry 46:96PubMedCrossRefGoogle Scholar
  19. Marcusson JO, Alafuzoff I, Bäckström IT, Ericson E, Gottfries CG, Winblad B (1987) 5-hydroxytryptamine-sensitive (3H)imipramine binding of protein nature in the human brain. II. Effect of normal aging and dementia disorders. Brain Res 425:137–145PubMedCrossRefGoogle Scholar
  20. Nagatsu T, Iizuka R (1989) Tyrosine hydroxylase, tryptophan hydroxylase, and the biopterin k-factor in the brains from patients with Alzheimer’s disease. J Neural Transm 1:21CrossRefGoogle Scholar
  21. Nyth AL, Gottfries CG, Elgen K, Engedal K, Harenko A, Juhela P, Karlsson I, Koskinen T, Nygaard H, Pedersen W, Samuelsson SM, Yli-Kerttula A (1989) The clinical efficacy of citalopram in the treatment of emotional disturbances in dementia disorders. A Nordic multi-centre studyGoogle Scholar
  22. Oreland L, Gottfries CG (1986) Platelet and brain monoamine oxidase in aging and in dementia of Alzheimer’s type. Prog Neuropsychopharmacol Biol Psychiatry 10:533–540PubMedCrossRefGoogle Scholar
  23. Regland B, Gottfries CG, Oreland L, Svennerholm L (1988) Low B12 levels related to high activity of platelet MAO in patients with dementia disorders. A retrospective study. Acta Psychiatr Scand 78:451–457PubMedCrossRefGoogle Scholar
  24. Regland B, Gottfries CG, Oreland L (1989) Vitamin B12 induced reduction of platelets MAO in patients with dementia and pernicious anaemia (to be published)Google Scholar
  25. Thomas DR, Jones E, Warner N, Harris B, Williams P, Bentley P (1988) Peripheral serotoninergic receptor sensitivity in senile dementia of the Alzheimer type. Biol Psychiatry 23:136–140PubMedCrossRefGoogle Scholar
  26. Wallin A, Alafuzoff I, Carlsson A, Eckernäs SÅ, Gottfries CG, Karlsson I, Svennerholm L, Winblad B(1989) Neurotransmitter deficits in a non-multi-infarct category of vascular dementia. Acta Neurol Scand 79:397–406PubMedCrossRefGoogle Scholar
  27. Widerlöv E, Ekman R, Jensen L, Borglund L, Nyman K (1988) Arginine vasopressin, but not corticopropin releasing factor, is a potent stimulator of adrenocorticotropic hormone following electroconvulsive treatment. J Neural Transm 75:101–109CrossRefGoogle Scholar

Copyright information

© Springer-Verlag 1990

Authors and Affiliations

  • C. G. Gottfries
    • 1
  1. 1.Department of Psychiatry and NeurochemistryGothenburg UniversityHisings BackaSweden

Personalised recommendations